101 related articles for article (PubMed ID: 25221955)
1. VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis.
Maa HC; Chao TT; Wang CY; Pei D; Liang YJ; Chen YL
Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):209-14. PubMed ID: 25221955
[TBL] [Abstract][Full Text] [Related]
2. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.
Lieser EA; Croghan GA; Nevala WK; Bradshaw MJ; Markovic SN; Mansfield AS
Lung Cancer; 2013 Oct; 82(1):63-8. PubMed ID: 23948549
[TBL] [Abstract][Full Text] [Related]
4. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
Conner JR; Cibas ES; Hornick JL; Qian X
Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
Zebrowski BK; Yano S; Liu W; Shaheen RM; Hicklin DJ; Putnam JB; Ellis LM
Clin Cancer Res; 1999 Nov; 5(11):3364-8. PubMed ID: 10589746
[TBL] [Abstract][Full Text] [Related]
6. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.
Zhang Y; Yu LK; Lu GJ; Xia N; Xie HY; Hu W; Hao KK; Xu CH; Qian Q
Asian Pac J Cancer Prev; 2014; 15(19):8435-40. PubMed ID: 25339042
[TBL] [Abstract][Full Text] [Related]
7. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.
Duysinx BC; Corhay JL; Hubin L; Nguyen D; Henket M; Louis R
Respir Med; 2008 Dec; 102(12):1708-14. PubMed ID: 18760578
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of metabolic phenotypes in malignant pleural effusions: expression of GLUT1 and CAIX by immunocytochemistry.
Liao ND; Shieh JM; Lee WY
Cancer Cytopathol; 2011 Oct; 119(5):346-53. PubMed ID: 21442770
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural effusions due to small-cell lung carcinoma: a cytologic and immunocytochemical study.
Chhieng DC; Ko EC; Yee HT; Shultz JJ; Dorvault CC; Eltoum IA
Diagn Cytopathol; 2001 Dec; 25(6):356-60. PubMed ID: 11747231
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor in malignant and tuberculous pleural effusions.
Lim SC; Jung SI; Kim YC; Park KO
J Korean Med Sci; 2000 Jun; 15(3):279-83. PubMed ID: 10895968
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of LUNX mRNA and VEGF mRNA in pleural fluid for differentiating benign from malignant origin.
Bao QL; Li J; Sun W; Jiang HG; Zhu LR; Wang Y
Jpn J Clin Oncol; 2014 Dec; 44(12):1198-205. PubMed ID: 25425729
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions.
Zhou WB; Bai M; Jin Y
Int J Tuberc Lung Dis; 2009 Mar; 13(3):381-6. PubMed ID: 19275801
[TBL] [Abstract][Full Text] [Related]
14. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of vascular endothelial growth factor (VEGF) in neoplastic and tuberculosis effusions--preliminary results].
Jankowska R; Porebska I; Dyła T
Pneumonol Alergol Pol; 2002; 70(5-6):258-64. PubMed ID: 12518624
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
17. Metastatic thyroid carcinoma presenting as malignant pleural effusion: A cytologic review of 5 cases.
Vyas M; Harigopal M
Diagn Cytopathol; 2016 Dec; 44(12):1085-1089. PubMed ID: 27456348
[TBL] [Abstract][Full Text] [Related]
18. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer.
Yanagawa H; Takeuchi E; Suzuki Y; Ohmoto Y; Bando H; Sone S
Cancer Immunol Immunother; 1999 Oct; 48(7):396-400. PubMed ID: 10501853
[TBL] [Abstract][Full Text] [Related]
20. Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
Rehnberg J; Zendehrokh N; Dejmek A
Anal Quant Cytol Histol; 2007 Aug; 29(4):217-20. PubMed ID: 17879629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
